CEL-SCI Advances Multikine Confirmatory Trial but Faces Cash Crunch, Needs ~$30M

CEL-SCI Corporation (NYSE: CVM) - Q3 2025 quick take

What's happening inside: Management is advancing a planned 212‑patient confirmatory registration study for Multikine while continuing to fund operations with equity raises. The company reduced operating losses vs. prior year but remains unprofitable, has a tight cash runway and discloses substantial doubt about its ability to continue as a going concern.

Key facts & numbers (as reported)

- Cash and cash equivalents (June 30, 2025): $1,792,856 (down from $4,738,173 at 9/30/2024)

- Total assets: $20,336,199 (vs. $26,991,766)

- Total liabilities: $13,311,259 (vs. $14,124,683)

- Stockholders' equity: $7,024,940 (vs. $12,867,083)

- Common shares issued and outstanding (June 30, 2025): 5,321,341; reported outstanding 6,882,156 as of August 13, 2025

- Nine months ended June 30, 2025 - Total operating expenses: $18,776,404 (2024: $20,232,070)

- Nine months R&D expense: $12,184,276 (2024: $13,684,204)

- Nine months net loss: $(19,310,155) (2024: $(20,810,973))

- Net loss per share - nine months: $(6.34) (2024: $(12.51)) - weighted avg shares 3,046,400 (2024: 1,715,982)

- Three months ended June 30, 2025 net loss: $(5,664,704) (2024: $(6,856,558))

- Net cash used in operating activities (9 months): $(12,449,214)

- Net cash provided by financing activities (9 months): $9,536,851 (proceeds from stock offerings and pre-funded warrants)

- Finance lease liabilities (net): $8,478,000 (future finance-lease obligation PV: $9,731,000 less imputed interest)

- Estimated cost to complete confirmatory study: ~$30 million (management's estimate)

- Significant non-cash charges (9 months): share‑based compensation (employees + non‑employees) ≈ $2,057,776; depreciation & amortization ≈ $2,924,303; patent impairment $13,312

- Subsequent event: July 14, 2025 offering - 1,500,000 shares sold at $3.82 for gross ≈ $5.7 million (reported)

Positive aspects (income statement & operations)

- Operating loss narrowed year‑over‑year: total operating expenses decreased to $18.78M from $20.23M.

- R&D spending declined (nine months) to $12.18M from $13.68M - management attributes part of the decline to lower share‑based compensation and some program cost reductions.

- Net loss improved slightly in both three‑ and nine‑month comparisons (absolute dollars and per‑share basis), aided by equity financings that increased shares outstanding (reducing EPS volatility).

- Company completed peer‑review publication and continues to present strong Phase 3 survival data for Multikine; FDA indicated the company may proceed with a confirmatory registration study.

Negative aspects (income statement & financial health)

- Company remains deeply unprofitable: nine‑month net loss $19.31M and continuing recurring losses.

- Cash burn is high: operating cash use $(12.45M) in nine months and ending cash only $1.79M at 6/30/2025 (although a July offering raised additional proceeds).

- Substantial doubt disclosed about going concern - company needs material additional financing to execute the confirmatory trial (~$30M) and sustain operations.

- Heavy lease obligations and finance-lease interest (finance lease PV ≈ $8.48M) plus a $2.3M deposit tied to the San Tomas lease reduce liquidity flexibility.

- Significant non‑cash compensation and dilution activity: large increases in additional paid‑in capital ($540.3M) reflect ongoing equity financings and share issuance; weighted average shares increased materially, complicating EPS comparability.

What to watch next

- Progress and timing of the 212‑patient confirmatory trial (start date depends on capital raise).

- Additional financing activity and cash runway updates (management estimates and subsequent July 2025 raise partially address this risk).

- Any material changes to lease obligations or refinancing of existing liabilities that affect liquidity.

- Regulatory interactions with FDA/EMA and any guidance on potential accelerated or conditional approval pathways for Multikine.

Bottom line: CEL-SCI (NYSE: CVM) is advancing a potentially high‑value clinical program with strong Phase 3 survival data, but the company remains loss‑making, cash‑constrained and dependent on further financings to run the confirmatory study and reach commercialization milestones.